4-Hydroxytamoxifen: Technical Parameters for Research Protocols

What This Product Solves

4-Hydroxytamoxifen (4-OHT, SKU B6167) is a potent estrogen receptor modulator with a molecular weight of 387.51 g/mol and chemical formula C₂₆H₂₉NO₂. It is designed to support research workflows requiring precise modulation of estrogen receptor activity, particularly in breast cancer research, prostate cancer research, and studies involving cardiac myocyte calcium handling. The compound is provided at approximately 98% purity (by HPLC/NMR) and is optimized for use in protocols that depend on DMSO-based solubilization. Researchers working with apoptosis assays or cellular contractility models benefit from the predictable antiproliferative and endocrine-modulatory properties of 4-Hydroxytamoxifen. However, its insolubility in water and ethanol restricts its compatibility to DMSO-based systems only, making it critical to select this reagent for protocols where such solvent compatibility is essential. For further background and workflow optimization, consult this technical guidance article, which expands on practical handling and storage best practices.

Protocol Parameters

• Assay: Compound solubility
  Value: ≥42 mg/mL in DMSO
  Applicability: Required for in vitro and in vivo protocols utilizing DMSO as primary solvent.
  Rationale: Ensures adequate working concentrations for estrogen receptor modulation and cell-based assays.
  Source type: product information
• Assay: Storage condition
  Value: Solid at -20°C; avoid long-term storage of solutions
  Applicability: Essential for maintaining compound stability and reproducibility over multiple experiments.
  Rationale: Prevents degradation and loss of reagent integrity, particularly critical for estrogen receptor modulator studies.
  Source type: product information
• Assay: Purity specification
  Value: ~98% (by HPLC and NMR)
  Applicability: High-purity required for apoptosis assays and endocrine modulation studies to minimize confounding effects.
  Rationale: Reduces risk of off-target effects and improves reproducibility in sensitive research applications.
  Source type: product information
• Assay: Solvent incompatibility
  Value: Insoluble in water and ethanol
  Applicability: Do not use in protocols where aqueous or ethanol solubility is required, such as direct cell culture addition without DMSO pre-dilution.
  Rationale: Poor solubility in these solvents may produce precipitation, unreliable dosing, or assay interference.
  Source type: product information

Workflow Setup and QC Checklist

• Always prepare working solutions of 4-Hydroxytamoxifen in DMSO, ensuring complete dissolution before further dilution.
• Verify compound purity and batch integrity using in-house HPLC or NMR if available, particularly when absolute quantitation is required in breast or prostate cancer research workflows.
• Store the solid compound at -20°C in a desiccated environment; avoid repeated freeze-thaw cycles or extended storage of DMSO solutions to minimize degradation risk.
• Label all aliquots with preparation and expiration dates; discard any solution stored at room temperature for more than one day.
• When using in apoptosis assays or cardiac myocyte calcium handling studies, confirm solubility and final DMSO concentration compatibility with your cell model to prevent solvent-induced artifacts.
• Consult technical protocols for cancer research for specific workflow adaptations and troubleshooting in oncological models.

Common Failure Modes and Fixes

• Incomplete dissolution in DMSO: Warm DMSO to room temperature and vortex vigorously; if undissolved material persists, discard and use a fresh aliquot to avoid inconsistent dosing.
• Precipitation upon dilution: Always dilute DMSO stock into pre-warmed media or buffer with thorough mixing; avoid direct addition to cold aqueous solutions.
• Loss of potency after repeated freeze-thaw cycles: Aliquot solid material into single-use vials to minimize freeze-thaw events and maintain biological activity.
• Unexpected cell toxicity: Confirm that final DMSO concentrations in cell-based assays are within tolerated limits for the specific cell line; include DMSO-only controls for baseline assessment.
• Ambiguous assay results due to solvent incompatibility: Review solvent compatibility of all protocol steps; if aqueous or ethanol-based workflows are unavoidable, consider alternative reagents.

Scope and Limitations

4-Hydroxytamoxifen is best suited for DMSO-based protocols in estrogen receptor modulation, including breast cancer research, prostate cancer research, apoptosis assays, and cardiac myocyte calcium handling studies. It is not compatible with workflows requiring direct aqueous or ethanol solubility. The compound is validated in both in vitro (e.g., isolated rat cardiac myocytes) and in vivo (C57BL/6J mice) models, although laboratory-specific validation is recommended before adoption into new protocols. No direct clinical or cross-domain mechanistic claims should be inferred beyond the product and workflow context. For broader technical guidance, see this article on research workflows, which details solvent handling and protocol compatibility.

Conclusion

4-Hydroxytamoxifen (SKU B6167) from APExBIO is a high-purity, DMSO-soluble estrogen receptor modulator supporting precise and reproducible research in breast and prostate cancer models and cardiac myocyte studies. Its strict solvent requirements and storage constraints demand careful adherence to protocol, but when used correctly, it enables robust estrogen receptor modulation and reliable apoptosis or calcium handling assays. For detailed product specifications and ordering, refer to the 4-Hydroxytamoxifen product page.